{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T21:53:32Z","timestamp":1793224412323,"version":"4.5.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2020,5,25]],"date-time":"2020-05-25T00:00:00Z","timestamp":1590364800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,25]],"date-time":"2020-05-25T00:00:00Z","timestamp":1590364800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","award":["TRP 6540-18"],"award-info":[{"award-number":["TRP 6540-18"]}],"id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","award":["MCL 7000-18"],"award-info":[{"award-number":["MCL 7000-18"]}],"id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["SPORE 2P50CA107399"],"award-info":[{"award-number":["SPORE 2P50CA107399"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["1R21CA223141"],"award-info":[{"award-number":["1R21CA223141"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["CA170783"],"award-info":[{"award-number":["CA170783"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>B-cell malignancies can potentially be cured by CD19 chimeric antigen receptor (CAR) T-cell therapy. Although clinical response rates can be up to 93% in acute lymphoblastic leukemia, treatment-related antigen loss and lack of therapeutic persistence contribute to disease relapse. These shortcomings of current CAR T-cell therapy indicate the need for biologically relevant target selection and for improving the efficacy and persistence of the CAR T cells, which we have addressed by developing a novel B-cell activating factor receptor (BAFF-R) CAR T-cell therapy with improved therapeutic persistence. BAFF-R is a B-cell survival receptor and highly expressed in B-cell malignancies. We developed a prototype CAR T cell that efficiently and specifically eliminated BAFF-R expressing human B-cell tumors in several xenogeneic mouse models, including models of CD19 antigen loss. We proceeded with translational development and validation of BAFF-R CAR T cells produced under current good manufacturing practices (cGMP). cGMP-grade BAFF-R CAR T cells underwent in vitro and in vivo validation in established models to confirm that the potency and efficacy of our original research modeling was replicated. Food and Drug Administration required release testing was performed to ensure our BAFF-R CAR T cells meet specifications for new drug products. Completing and exceeding these requirements, the data fully support the initiation of a first-in-human Phase 1 trial for BAFF-R-positive relapsed\/refractory (r\/r) B-ALL.<\/jats:p>","DOI":"10.1007\/s00262-020-02614-8","type":"journal-article","created":{"date-parts":[[2020,5,25]],"date-time":"2020-05-25T17:02:30Z","timestamp":1590426150000},"page":"2139-2145","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Antitumor efficacy of BAFF-R targeting CAR T cells manufactured under clinic-ready conditions"],"prefix":"10.1007","volume":"69","author":[{"given":"Zhenyuan","family":"Dong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wesley A.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Lynne","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiantian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Chung","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuli","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Forman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry W.","family":"Kwak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4686-929X","authenticated-orcid":false,"given":"Hong","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,25]]},"reference":[{"key":"2614_CR1","doi-asserted-by":"publisher","first-page":"e577","DOI":"10.1038\/bcj.2017.53","volume":"7","author":"T Terwilliger","year":"2017","unstructured":"Terwilliger T, Abdul-Hay M (2017) Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer J 7:e577. https:\/\/doi.org\/10.1038\/bcj.2017.53","journal-title":"Blood Cancer J"},{"key":"2614_CR2","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1002\/cncr.29383","volume":"121","author":"E Jabbour","year":"2015","unstructured":"Jabbour E, O\u2019Brien S, Konopleva M, Kantarjian H (2015) New insights into the pathophysiology and therapy of adult acute lymphoblastic leukemia. Cancer 121:2517\u20132528. https:\/\/doi.org\/10.1002\/cncr.29383","journal-title":"Cancer"},{"key":"2614_CR3","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1182\/blood.V128.22.221.221","volume":"128","author":"SA Grupp","year":"2016","unstructured":"Grupp SA, Laetsch TW, Buechner J et al (2016) Analysis of a global registration trial of the efficacy and safety of CTL019 in pediatric and young adults with relapsed\/refractory acute lymphoblastic leukemia (ALL). Blood 128:221","journal-title":"Blood"},{"key":"2614_CR4","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J et al (2018) Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. New Engl J Med 378:439\u2013448. https:\/\/doi.org\/10.1056\/NEJMoa1709866","journal-title":"New Engl J Med"},{"key":"2614_CR5","doi-asserted-by":"publisher","first-page":"3814","DOI":"10.1172\/JCI87366","volume":"126","author":"M Ruella","year":"2016","unstructured":"Ruella M, Barrett DM, Kenderian SS et al (2016) Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies. J Clin Investig 126:3814\u20133826. https:\/\/doi.org\/10.1172\/JCI87366","journal-title":"J Clin Investig"},{"key":"2614_CR6","doi-asserted-by":"publisher","first-page":"eaaw9414","DOI":"10.1126\/scitranslmed.aaw9414","volume":"11","author":"H Qin","year":"2019","unstructured":"Qin H, Dong Z, Wang X et al (2019) CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies. Science translational medicine. 11:eaaw9414. https:\/\/doi.org\/10.1126\/scitranslmed.aaw9414","journal-title":"Science translational medicine."},{"key":"2614_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12013-008-9036-1","volume":"53","author":"JF Treml","year":"2009","unstructured":"Treml JF, Hao Y, Stadanlick JE, Cancro MP (2009) The BLyS family: toward a molecular understanding of B cell homeostasis. Cell Biochem Biophys 53:1\u201316. https:\/\/doi.org\/10.1007\/s12013-008-9036-1","journal-title":"Cell Biochem Biophys"},{"key":"2614_CR8","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1016\/j.humpath.2005.08.005","volume":"36","author":"SJ Rodig","year":"2005","unstructured":"Rodig SJ, Shahsafaei A, Li B, Mackay CR, Dorfman DM (2005) BAFF-R, the major B cell-activating factor receptor, is expressed on most mature B cells and B-cell lymphoproliferative disorders. Hum Pathol 36:1113\u20131119. https:\/\/doi.org\/10.1016\/j.humpath.2005.08.005","journal-title":"Hum Pathol"},{"key":"2614_CR9","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1182\/blood-2004-02-0762","volume":"104","author":"AJ Novak","year":"2004","unstructured":"Novak AJ, Grote DM, Stenson M et al (2004) Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome. Blood 104:2247\u20132253. https:\/\/doi.org\/10.1182\/blood-2004-02-0762","journal-title":"Blood"},{"key":"2614_CR10","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1158\/1078-0432.CCR-17-1193","volume":"24","author":"H Qin","year":"2018","unstructured":"Qin H, Wei G, Sakamaki I et al (2018) Novel BAFF-receptor antibody to natively folded recombinant protein eliminates drug-resistant human B-cell malignancies in vivo. Clin Cancer Res 24:1114\u20131123. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-1193","journal-title":"Clin Cancer Res"},{"key":"2614_CR11","doi-asserted-by":"publisher","first-page":"2980","DOI":"10.1182\/blood-2015-12-686725","volume":"127","author":"X Wang","year":"2016","unstructured":"Wang X, Popplewell LL, Wagner JR et al (2016) Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL. Blood 127:2980\u20132990. https:\/\/doi.org\/10.1182\/blood-2015-12-686725","journal-title":"Blood"},{"key":"2614_CR12","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1182\/blood-2010-10-310599","volume":"117","author":"X Wang","year":"2011","unstructured":"Wang X, Berger C, Wong CW, Forman SJ, Riddell SR, Jensen MC (2011) Engraftment of human central memory-derived effector CD8+ T cells in immunodeficient mice. Blood 117:1888\u20131898. https:\/\/doi.org\/10.1182\/blood-2010-10-310599","journal-title":"Blood"},{"key":"2614_CR13","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1097\/CJI.0b013e318270dec7","volume":"35","author":"X Wang","year":"2012","unstructured":"Wang X, Naranjo A, Brown CE et al (2012) Phenotypic and functional attributes of lentivirus-modified CD19-specific human CD8+ central memory T cells manufactured at clinical scale. J Immunother 35:689\u2013701. https:\/\/doi.org\/10.1097\/CJI.0b013e318270dec7","journal-title":"J Immunother"},{"key":"2614_CR14","doi-asserted-by":"publisher","first-page":"254","DOI":"10.3389\/fphar.2014.00254","volume":"5","author":"BS Jones","year":"2014","unstructured":"Jones BS, Lamb LS, Goldman F, Di Stasi A (2014) Improving the safety of cell therapy products by suicide gene transfer. Front Pharmacol 5:254. https:\/\/doi.org\/10.3389\/fphar.2014.00254","journal-title":"Front Pharmacol"},{"key":"2614_CR15","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaw9414","author":"H Qin","year":"2019","unstructured":"Qin H, Dong Z, Wang X et al (2019) CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies. Sci Transl Med. https:\/\/doi.org\/10.1126\/scitranslmed.aaw9414","journal-title":"Sci Transl Med"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-020-02614-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-020-02614-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-020-02614-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T19:23:12Z","timestamp":1621884192000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-020-02614-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,25]]},"references-count":15,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["2614"],"URL":"https:\/\/doi.org\/10.1007\/s00262-020-02614-8","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,25]]},"assertion":[{"value":"6 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"LWK and HQ have license agreements with and receive research support from Pepromene Bio Inc. All other authors declare no competing financial interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}